In conclusion, the results of this clinical trial provide evidence that AZD9150, a next-generation ASO inhibitor of STAT3 mRNA, is safe and appears to benefit some patients with heavily pretreated DLBCL. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.